Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ: ABCL ) with a Buy and raises the price target from $12 to $30.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.